Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp (SLXN) is asking shareholders at a September 9, 2026 extraordinary general meeting to approve two capital-structure changes aimed at preserving its Nasdaq Capital Market listing and funding development of its RNAi oncology programs.
Proposal 1 would increase authorized share capital by 175,000,000 ordinary shares, from 15,900,000 to 190,900,000 shares (par value $0.135), an 1,100% increase in authorization. As of August 24, 2026, 5,755,872 ordinary shares were outstanding and significant portions of the remaining authorization are reserved for warrants, equity plans, an at-the-market program, and a promissory note to Moringa Sponsor, L.P.; an internal table shows the current plan usage would exceed the 15.9 million authorized shares. Management links this increase to maintaining compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of shareholders’ equity, and to providing capacity for future financings and business development.
Proposal 2 would authorize a reverse share split of all issued and authorized ordinary shares at a ratio between 1-for-7 and 1-for-15, with the exact ratio set by the board before the meeting. The split is intended to support compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Rule 5550(a)(2); Silexion has already completed 1-for-9, 1-for-15, and 1-for-10 reverse splits since 2024. The board states that percentage ownership and voting rights per holder will remain the same, except for rounding of fractional shares, and that authorized share count and par value will be adjusted proportionally.
Silexion Therapeutics Corp (SLXN) reports that on August 18, 2026 it received a Nasdaq delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2,500,000 shareholders’ equity requirement under Listing Rule 5550(b)(1). The company’s Form 10-Q for June 30, 2026 reported shareholders’ equity of $44,000, and it does not meet alternative continued listing standards. Silexion, already under a Mandatory Hearings Panel Monitor, plans to appeal to a Nasdaq Hearings Panel by August 25, 2026 and present steps taken and planned to restore equity compliance. The company states there is no assurance the appeal will succeed or that additional time will be granted; if unsuccessful, trading in its ordinary shares and warrants would be suspended and a Form 25-NSE would remove them from Nasdaq.
Silexion Therapeutics Corp (SLXN) is the subject of a Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership. As of the close of business on August 18, 2026, they may be deemed to beneficially own 286,866 Ordinary Shares, including shares underlying several warrants, representing 4.99% of Silexion’s Ordinary Shares. This position reflects a Securities Purchase Agreement dated August 11, 2026 and multiple Intracoastal warrants that contain blocker provisions limiting exercises so that the Reporting Persons’ beneficial ownership does not exceed specified percentage thresholds (primarily 4.99% or 9.99%). All voting and dispositive power is reported as shared, with no sole power over the shares.
Silexion Therapeutics Corp is calling an extraordinary general meeting in September 2026 to ask shareholders to approve two capital structure changes. Proposal 1 would increase authorized share capital by 175,000,000 ordinary shares, from 15,900,000 to 190,900,000 ordinary shares (par value US$0.135), raising authorized capital from US$2,146,500 to US$25,771,500. The company states this is intended to preserve compliance with Nasdaq’s US$2.5 million minimum shareholders’ equity requirement and to fund operations, including Phase 2/3 clinical trials for SIL204 and potential business development transactions.
As of August 13, 2026, 5,560,256 ordinary shares were outstanding, and the company estimates its shareholders’ equity (as of June 30, 2026, adjusted for subsequent transactions) at approximately US$3.2 million. It shows current authorized capacity is effectively over-allocated once warrants, equity plans, ATM sales assumptions and the A&R Sponsor Promissory Note are considered.
Proposal 2 would authorize a reverse share split of all issued and authorized ordinary shares at a ratio between 1-for-7 and 1-for-15, to be set by the board before the meeting. The stated purpose is to maintain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum US$1.00 bid price, following prior reverse splits of 1-for-9, 1-for-15 and 1-for-10. Both proposals require approval by an ordinary resolution of shareholders present and voting; abstentions and broker non-votes do not count as votes cast. The board recommends voting in favor of each proposal.
Silexion Therapeutics Corp is a clinical-stage biotech focused on RNAi therapies for KRAS-driven cancers, led by SIL204 for locally advanced pancreatic cancer. Regulatory approvals in Israel and Germany allow a Phase 2/3 trial, with first site in Tel Aviv activated shortly after quarter-end.
For the six months ended June 30, 2026, Silexion reported a net loss of $6.3 million (up from $4.2 million), driven by higher R&D expenses of $3.6 million and G&A of $2.8 million. Cash and cash equivalents were $2.2 million, total assets $4.2 million, and shareholders’ equity only $44 thousand. Operating cash outflow was $6.6 million, and the company discloses substantial doubt about its ability to continue as a going concern, estimating its current funds cover only several months.
To fund operations, Silexion relies on dilutive equity financings, including public offerings, induced warrant exercises, and an at-the-market program under which about $2.0 million (net) was raised in the first half of 2026 and an additional $0.3 million thereafter. A related-party promissory note was partly converted to equity. After an August 2026 offering and other transactions, pro forma shareholders’ equity is described as approximately $3.2 million, restoring compliance with Nasdaq’s $2.5 million equity requirement, but the company remains dependent on continued market access and has recently executed multiple reverse share splits to support its listing and financing capacity.
Silexion Therapeutics Corp reported larger losses for the three and six months ended June 30, 2026 while advancing its lead RNAi candidate SIL204 into an active Phase 2/3 trial in locally advanced pancreatic cancer. Regulatory approvals in Israel and from Germany’s BfArM enabled trial initiation, with the first site activated at Tel Aviv Sourasky Medical Center in July 2026 and additional Israeli and German sites progressing toward activation. New preclinical immuno-oncology data showed statistically significant effects on MHC-I, FAS (CD95), and HLA-G across four KRAS mutations, supporting future combination with anti-PD-(L)1 checkpoint inhibitors.
R&D expenses rose to $2.2 million in the quarter and $3.6 million year-to-date, driving a net loss of $3.6 million for the quarter and $6.3 million for the six months. Cash and cash equivalents declined to $2.2 million and total assets to $4.2 million, while shareholders’ equity narrowed to $44 thousand. The company executed multiple capital-structure actions, including a 1-for-10 reverse split and a registered public offering with $2.5 million gross proceeds and approximately $2.1 million net proceeds, and highlighted substantial doubt about its ability to continue as a going concern in its financial statements.
Silexion Therapeutics Corp reported updated historical financials to reflect a previously approved 1-for-10 reverse share split, on top of earlier 1-for-9 and 1-for-15 splits. All shares, per‑share data, options and warrants for 2024–2025 and March 31, 2026 have been retroactively adjusted.
For 2025, Silexion, a clinical‑stage RNAi oncology company with no revenues, recorded a net loss of $11.9 million and negative operating cash flow of $10.8 million. Cash and cash equivalents were $6.0 million and total assets $7.2 million as of December 31, 2025, against an accumulated deficit of $55.2 million. Shareholders’ equity improved from a deficit of $4.0 million at year‑end 2024 to positive equity of $2.6 million, mainly through public offerings, warrant exercises and note conversions.
The independent auditor issued an unqualified opinion but highlighted substantial doubt about Silexion’s ability to continue as a going concern, citing recurring operating losses, negative operating cash flows and limited liquidity. Management discloses that existing cash is expected to fund operations for only several months from the financial statement issuance date and that additional financing will be required.
Silexion Therapeutics Corp completed a best-efforts public offering of equity and warrants. The company sold 2,028,619 ordinary shares, 1,817,542 pre-funded warrants and 3,846,161 Series E ordinary warrants at a combined price of $0.65 per share and accompanying warrant (and $0.6499 per pre-funded warrant and accompanying warrant), generating approximately $2.5 million in gross proceeds and about $2.1 million in net proceeds. The Series E warrants are immediately exercisable at $0.65 per share for five years; the pre-funded warrants are exercisable at $0.0001 per share until fully exercised.
The company also issued 269,231 placement agent warrants at an exercise price of $0.8125 and paid the placement agent an 8% combined cash and management fee plus expenses. In connection with the closing, Silexion converted $750,001 of its sponsor note into 1,153,848 ordinary shares at $0.65 per share, reducing the note balance to $206,462. After the offering, note conversion, ATM sales and pre-funded warrant exercises, Silexion preliminarily estimates shareholders’ equity at approximately $3.2 million, and plans to use the proceeds primarily to advance its SIL204 clinical trial and for general corporate purposes.
Silexion Therapeutics Corp, a clinical-stage oncology biotech focused on RNA interference therapies for KRAS-driven cancers, is conducting a best-efforts primary offering of 2,028,619 ordinary shares together with 3,846,161 ordinary warrants at a public offering price of $0.65 per share and accompanying warrant. Purchasers that would otherwise exceed 4.99% or 9.99% beneficial ownership may instead purchase up to 1,817,542 pre-funded warrants at $0.6499 each, each paired with one ordinary warrant. The ordinary warrants have a $0.65 exercise price and a five-year term; the pre-funded warrants are exercisable at $0.0001 per share until fully exercised. Gross proceeds total about $2.50 million, with estimated net proceeds of roughly $2.1 million after placement fees, to be used to advance pre-clinical and clinical studies and for general corporate purposes. The company’s ordinary shares and warrants trade on the Nasdaq Capital Market as “SLXN” and “SLXNW.” Silexion is advancing lead candidate SIL204 for locally advanced pancreatic cancer and has received regulatory clearances in Israel and Germany to initiate a Phase 2/3 trial, which has begun enrollment at an initial Israeli site. The company reports substantial doubt about its ability to continue as a going concern and is also using this financing to help support compliance with Nasdaq shareholders’ equity requirements.